Trademark: 90755107
Word
BEXLAMDA
Status
Pending
Status Code
732
Status Date
Friday, April 5, 2024
Serial Number
90755107
Mark Type
4000
Filing Date
Friday, June 4, 2021
Published for Opposition
Tuesday, September 27, 2022

Trademark Owner History
Bristol-Myers Squibb Company - Owner At Publication

Classifications
5 Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use in the nature of monoclonal antibodies for medical purposes

Trademark Events
Apr 6, 2024
Notice Of Approval Of Extension Request E-Mailed
Apr 5, 2024
Sou Extension 3 Granted
Apr 5, 2024
Sou Extension 3 Filed
Apr 5, 2024
Sou Teas Extension Received
Nov 22, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 20, 2023
Sou Extension 2 Granted
Nov 20, 2023
Sou Extension 2 Filed
Nov 20, 2023
Sou Teas Extension Received
Aug 2, 2023
Teas Change Of Correspondence Received
Aug 2, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 2, 2023
Teas Change Of Owner Address Received
May 2, 2023
Notice Of Approval Of Extension Request E-Mailed
Apr 28, 2023
Sou Extension 1 Granted
Apr 28, 2023
Sou Extension 1 Filed
Apr 28, 2023
Sou Teas Extension Received
Nov 22, 2022
Noa E-Mailed - Sou Required From Applicant
Sep 27, 2022
Official Gazette Publication Confirmation E-Mailed
Sep 27, 2022
Published For Opposition
Sep 7, 2022
Notification Of Notice Of Publication E-Mailed
Aug 19, 2022
Approved For Pub - Principal Register
Aug 19, 2022
Examiner's Amendment Entered
Aug 19, 2022
Notification Of Examiners Amendment E-Mailed
Aug 19, 2022
Examiners Amendment E-Mailed
Aug 19, 2022
Examiners Amendment -Written
Aug 12, 2022
Teas/Email Correspondence Entered
Aug 12, 2022
Correspondence Received In Law Office
Aug 12, 2022
Teas Response To Office Action Received
Feb 15, 2022
Notification Of Non-Final Action E-Mailed
Feb 15, 2022
Non-Final Action E-Mailed
Feb 15, 2022
Non-Final Action Written
Feb 10, 2022
Assigned To Examiner
Aug 26, 2021
New Application Office Supplied Data Entered
Jun 8, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24